Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Enabling a new era in minimally invasive obesity treatment across Europe
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated